1. Medtech Insight
  2. >>Policy & Regulation

CMS Announces FY 2015 New-Tech Add-On Payment Applicants

Among the latest round of applicants announced Dec. 26 for the hospital inpatient, new-technology add-on payments are five device makers: Boston Scientific (Watchman), CardioMEMS (Champion HF), Abbott Vascular (MitraClip), NeuroPace (RNS), and Aptus Endosystems (Heli-FX EndoAnchor).

CMS announced the latest round of applicants for new-technology add-on payments under the acute inpatient prospective payment system for FY 2015 on Dec. 26. Of the seven applicants, five are device- makers and two are pharmaceutical companies. CMS has scheduled a town hall meeting Feb. 12 to discuss the applications.

To win an add-on payment a device has to meet the criteria of being sufficiently new; it must have a cost that exceeds the standard Medicare payment for the procedure...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.